Our global animal health business is dedicated to preserving and improving the health, well-being and performance of animals through science.
We offer veterinarians, farmers, pet owners and governments the widest range of veterinary pharmaceuticals, parasiticides, vaccines and health management solutions. Healthier animals mean sustainable food supplies, protection against zoonotic diseases1, reduction of the burden of certain food-borne diseases, and longer, richer companionship for pet owners.
Our animal health business employs more than 6,500 people worldwide and is present in more than 50 countries.
2015 Performance Highlights
- Acquisition of Harrisvaccines, a privately held company that develops, manufactures and sells vaccines for food production and companion animals. Harrisvaccines has a unique RNA particle technology that represents a breakthrough in vaccine development. It also has a highly versatile production platform able to target a wide range of viruses and bacteria. In October 2015, Harrisvaccines was awarded an avian influenza stockpile contract from the United States Department of Agriculture (USDA) for the company’s avian influenza vaccine, RNA, which had been granted USDA conditional licensure earlier in 2015.
- European launch of PORCILIS® PCV M Hyo®, Europe’s first single-shot vaccine to protect piglets from both porcine circovirus type 2 and Mycoplasma hyopneumoniae PORCILIS PCV M Hyo comes ready to use and does not require mixing, saving labor and time, and reducing the potential for handling error.
- European approval for PORCILIS® PCV ID, the first intradermal vaccine against porcine circovirus type 2 (PCV2) that is administered with the needle-free IDAL® vaccine delivery system. With this addition to the company’s line of intradermal vaccines, swine producers will now have access to intradermal needle-free protection against PCV2, Mycoplasma hyopneumoniae (M. hyo) and porcine reproductive and respiratory syndrome virus (PRRSv), the three major swine diseases affecting pig operations worldwide.
- Global launch of the IDAL® 2G vaccination device for pigs. The second generation of our needle-free IDAL vaccine delivery system, IDAL 2G has additional features that give the user more information and make the system easier to use.
- European launch of INNOVAX®-ILT, our company’s novel vaccine that, in a single shot, protects poultry against infectious laryngotracheitis (ILT) as well as Marek’s disease, for use in the European Union. INNOVAX-ILT is our Animal Health Business’ first vector vaccine to launch in the EU, and is the first and only vector vaccine available in the EU to protect against ILT.
- USDA conditional product license for canine influenza vaccine H3N2, to protect against this newly identified strain of canine influenza virus, making the vaccine available to U.S. veterinarians
- Expansion of educational initiatives like the Convenience Program Evaluation, to help producers troubleshoot disease outbreaks, optimize vaccination processes, and maintain the health of their poultry the High Quality Congress website, to support producers of aquaculture, poultry and swine, bringing together a wide range of experts to discuss the latest advances in production and management across these species to ensure the success of producers by improving the health, productivity and well-being of their animals; and “Are you missing the signs?,” a global awareness campaign designed to help cat owners recognize the signs of feline hyperthyroidism.
Our animal health business employs more than 6,500 people worldwide and is present in more than 50 countries. We operate a global network of manufacturing sites and dedicated R&D facilities, and offer products for various species, including ruminants (cattle, sheep, goats), poultry, swine, aquatic animals and companion animals (dogs, cats, horses) in 150 countries. Our animal health business focuses our corporate responsibility efforts in the following areas:
- Protecting animal health
- Contributing to public health
- Supporting a sustainable, global food supply and managing our global footprint
- Ensuring ethical business practices
Note: This section includes information about how Merck & Co., Inc., Kenilworth, NJ, USA, contributes to societies through its Animal Health business. Information and data on the performance of our Animal Health business in the environment and in other areas is contained within the main sections of our global corporate responsibility report.
|1 Zoonotic diseases are any disease or infection that is naturally transmissible from vertebrate animals to humans or vice versa (World Health Organization). Food-borne diseases in general encompass a wide spectrum of illnesses caused by microbial, parasitic or chemical contamination of food.|
|Number of rabies vaccines donated annually to Afya projects (doses)1||200,000||200,000||280,000|
|Value of equine vaccines donated annually to the Unwanted Horse Veterinary Relief Campaign||$125,000||$115,000||$107,000|
|Number of annual rabies vaccinations carried out in collaboration with the Global Alliance for Rabies Control and the Bombay Veterinary College (doses)2||50,000||15,000||--|
|Number of new products approved (annually)||5||8||10|
|1 Afya project support in 2015 includes donations to Sarah Cleaveland’s efforts in the Serengeti and Mission Rabies.|
2 As of 2015, these funds have been transferred to Mission Rabies, which is carrying out rabies vaccination efforts in India and other regions.